| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1049163392 |
| P356 | DOI | 10.1007/S11926-007-0004-3 |
| P698 | PubMed publication ID | 17502040 |
| P2093 | author name string | Robin L Brey | |
| Jose F Roldan | |||
| P2860 | cites work | Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke | Q28167141 |
| Management of the neurological manifestations of APS--what do the trials tell us? | Q28171326 | ||
| Antiphospholipid antibodies in young adults with stroke | Q28192380 | ||
| Predictors of cognitive dysfunction in patients with systemic lupus erythematosus | Q28213684 | ||
| International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) | Q28292418 | ||
| Predictors of neuropsychiatric damage in systemic lupus erythematosus: data from the Maryland lupus cohort | Q30956012 | ||
| Hughes syndrome, the antiphospholipid syndrome: a new chapter in neurology | Q31001994 | ||
| Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. European Working Party on Systemic Lupus Erythematosus | Q33329033 | ||
| Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients | Q33341941 | ||
| Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients | Q33357081 | ||
| Antiphospholipid Thrombosis: Clinical Course after the First Thrombotic Event in 70 Patients | Q33369688 | ||
| Comparison of the effects of anticardiolipin antibodies from patients with the antiphospholipid syndrome and with syphilis on platelet activation and aggregation | Q33489097 | ||
| Anti-phospholipid syndrome: from patient's bedside to experimental animal models and back to the patient's bedside | Q33504563 | ||
| Transverse myelopathy in systemic lupus erythematosus: an analysis of 14 cases and review of the literature | Q33832953 | ||
| Perioperative medical management of antiphospholipid syndrome: hospital for special surgery experience, review of literature, and recommendations. | Q34597516 | ||
| Anticardiolipin antibodies in patients with multiple sclerosis do not represent a subgroup of patients according to clinical, familial, and biological characteristics. | Q35467118 | ||
| Intracellular signaling triggered by antiphospholipid antibodies in platelets and endothelial cells: a pathway to targeted therapies | Q35928725 | ||
| The interface of multiple sclerosis and antiphospholipid antibodies | Q35928731 | ||
| Epilepsy as part of systemic lupus erythematosus and systemic antiphospholipid syndrome (Hughes syndrome). | Q36473943 | ||
| Cardiac manifestations in the antiphospholipid syndrome | Q36552685 | ||
| Antiphospholipid antibodies in an in vivo thrombosis model in mice | Q40558495 | ||
| A prospective analysis of cognitive function and anticardiolipin antibodies in systemic lupus erythematosus | Q41647250 | ||
| Do antiphospholipid antibodies increase the long-term risk of thrombotic complications in young patients with a recent TIA or ischemic stroke? | Q43717978 | ||
| Using 99mTc HMPAO brain SPECT to evaluate the effects of anticoagulant therapy on regional cerebral blood flow in primary antiphospholipid antibody syndrome patients with brain involvement-a preliminary report | Q44396576 | ||
| A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome | Q44588720 | ||
| Antiphospholipid antibodies bind to activated but not resting endothelial cells: is an independent triggering event required to induce antiphospholipid antibody-mediated disease? | Q45014887 | ||
| Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. | Q47928982 | ||
| MRI findings in central nervous system systemic lupus erythematosus are associated with immunoserological parameters and hypertension | Q48129276 | ||
| Neuropsychological deficits associated with antiphospholipid antibodies | Q48149596 | ||
| Cerebral magnetic resonance imaging in patients with or without antiphospholipid antibodies | Q48491099 | ||
| Lupus anticoagulant and anticardiolipin antibodies in young adults with cerebral ischemia | Q48537242 | ||
| Positron emission tomography and magnetic resonance imaging for cerebral involvement in patients with systemic lupus erythematosus | Q48793158 | ||
| Anticardiolipin antibodies in normal subjects. Neuropsychological correlates and MRI findings | Q49226626 | ||
| Neuropsychological functioning and its relationship to antiphospholipid antibodies in patients with systemic lupus erythematosus. | Q52011027 | ||
| Epileptic seizures in systemic lupus erythematosus | Q57086591 | ||
| Anticardiolipin antibodies are not a useful screening tool in a nonselected large group of patients with multiple sclerosis | Q57602063 | ||
| Lack of association between anticardiolipin antibodies and migraine in systemic lupus erythematosus | Q57602230 | ||
| Anticardiolipin Antibodies and Physical Disability in the Elderly | Q57606069 | ||
| Increased anticardiolipin antibody IgG titers do not predict recurrent stroke or TIA in children | Q58320246 | ||
| Dementia and Antiphospholipid Antibodies | Q59416893 | ||
| Letters to the Editor | Q59489866 | ||
| Association of antiphospholipid antibodies with central nervous system disease in systemic lupus erythematosus | Q71775354 | ||
| The management of thrombosis in the antiphospholipid-antibody syndrome | Q72619159 | ||
| The relationship of antiphospholipid antibodies to cognitive function in patients with systemic lupus erythematosus | Q73594631 | ||
| Systemic autoimmune features and multiple sclerosis: a 5-year follow-up study | Q74485208 | ||
| Role of anticardiolipin antibodies in young persons with migraine and transient focal neurologic events: a prospective study | Q74575122 | ||
| A longitudinal study of anticardiolipin antibody levels and cognitive functioning in systemic lupus erythematosus | Q77352546 | ||
| Induction of antiphospholipid antibodies by immunization with synthetic viral and bacterial peptides | Q78248010 | ||
| Prospective assessment of risk factors for recurrent stroke during childhood--a 5-year follow-up study | Q78549911 | ||
| P433 | issue | 2 | |
| P921 | main subject | antiphospholipid syndrome | Q582207 |
| P304 | page(s) | 109-115 | |
| P577 | publication date | 2007-05-01 | |
| P1433 | published in | Current Rheumatology Reports | Q23930052 |
| P1476 | title | Neurologic manifestations of the antiphospholipid syndrome | |
| P478 | volume | 9 |
| Q26824461 | A model for lupus brain disease |
| Q59808719 | Antiphospholipid Syndrome and the Neurologist: From Pathogenesis to Therapy |
| Q41200243 | Increased heterogeneity of brain perfusion is an early marker of central nervous system involvement in antiphospholipid antibody carriers. |
| Q42539014 | Neuropsychiatric systemic lupus erythematosus reconsidered |
| Q89453447 | Seronegative antiphospholipid syndrome: refining the value of "non-criteria" antibodies for diagnosis and clinical management |
Search more.